← 返回

乳腺癌/间充质干细胞杂交细胞群增强化疗耐药与转移

英文原题:A hybrid breast cancer/mesenchymal stem cell population enhances chemoresistance and metastasis.

查看英文原题

A hybrid breast cancer/mesenchymal stem cell population enhances chemoresistance and metastasis.

PubMed 2023/09/22(内容时间) JCI Insight Q1 · IF 6.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

尽管接受治疗,三阴性乳腺癌患者仍有转移风险。获得化疗耐药是肿瘤复发和死亡的主要原因之一,但其机制尚未充分阐明。我们已发现乳腺癌细胞(BCC)能够吞噬间充质干/基质细胞(MSC),从而增强播散能力。

本研究显示,原发浸润性癌和化疗耐药乳腺癌转移灶的临床样本中存在一种独特的杂合癌细胞群,同时表达广谱细胞角蛋白和 MSC 标志物成纤维细胞活化蛋白-α。

我们发现,杂合细胞可在原发肿瘤中形成,并促进乳腺癌转移及化疗耐药。通过单细胞微流控和体内模型,我们发现杂合细胞群中存在多倍体衰老细胞,这些细胞有助于转移播散。数据表明,Wnt 家族成员 5A(WNT5A)对支持杂合细胞的化疗耐药特性至关重要。

此外,我们发现 WNT5A 通过类似吞噬作用的机制介导杂合细胞形成,该过程需要 BCC 来源的 IL-6 和 MSC 来源的 C-C 基序趋化因子配体 2。

本研究揭示杂合细胞形成是化疗耐药的一种机制,并提示阻断这一机制可能有助于克服乳腺癌耐药。

展开英文摘要原文

Patients with triple-negative breast cancer remain at risk for metastatic disease despite treatment. The acquisition of chemoresistance is a major cause of tumor relapse and death, but the mechanisms are far from understood.

We have demonstrated that breast cancer cells (BCCs) can engulf mesenchymal stem/stromal cells (MSCs), leading to enhanced dissemination.

Here, we show that clinical samples of primary invasive carcinoma and chemoresistant breast cancer metastasis contain a unique hybrid cancer cell population coexpressing pancytokeratin and the MSC marker fibroblast activation protein- .

We show that hybrid cells form in primary tumors and that they promote breast cancer metastasis and chemoresistance. Using single-cell microfluidics and in vivo models, we found that there are polyploid senescent cells within the hybrid cell population that contribute to metastatic dissemination.

Our data reveal that Wnt Family Member 5A (WNT5A) plays a crucial role in supporting the chemoresistance properties of hybrid cells.

Furthermore, we identified that WNT5A mediates hybrid cell formation through a phagocytosis-like mechanism that requires BCC-derived IL-6 and MSC-derived C-C Motif Chemokine Ligand 2.

These findings reveal hybrid cell formation as a mechanism of chemoresistance and suggest that interrupting this mechanism may be a strategy in overcoming breast cancer drug resistance.

论文信息

作者
Augimeri G、Gonzalez ME、Paolì A、Eido A、Choi Y、Burman B、Djomehri S、Karthikeyan SK
单位
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.United States
文献类型
美国 NIH 资助研究 · 美国政府(非公共卫生署)资助研究
期刊
JCI insight2023 Sep 22
原文标识
PubMed 37607007 · DOI 10.1172/jci.insight.164216